Raxibacumab, officially designated as PAmAb ABthrax, represents a unique medication approach to the infection. This monoclonal antibody , designed by ProBioGen AG , uniquely binds to the protective component of Bacillus anthracis, demonstrably neutralizing its ability to trigger harm. The mechanism of Raxibacumab entails preventing toxin website at